| IV-01 Brigitte Lacroix A quantitative framework integrating exposure, efficacy, receptor occupancy and tolerability to propose evidence-based dose regimens for padsevonil Thursday 15:10-16:40 |
| IV-02 Shankar Lanke Population Pharmacokinetic Analyses of Tolvaptan in Subjects with Autosomal Dominant Polycystic Kidney Disease Thursday 15:10-16:40 |
| IV-03 Christian Laveille Population pharmacokinetics of Rimeporide in healthy volunteers and children suffering from Duchenne Muscular Dystrophy (DMD) Thursday 15:10-16:40 |
| IV-05 Robert Leary Automatic framework for bioequivalence studies from In Vitro test to In Vivo study design Thursday 15:10-16:40 |
| IV-06 Woo Yul Lee A population pharmacodynamic model of combination antidepressant therapy in depression Thursday 15:10-16:40 |
| IV-07 Quentin Leirens Clinical Trial Simulation of a Phase I Paediatric Oncology Study using Simulo Thursday 15:10-16:40 |
| IV-08 Jennifer Leohr A Categorical Model of Sweet/Fat Preference Taste in Lean, Obese and Very Obese Subjects Thursday 15:10-16:40 |
| IV-09 Giulia Lestini Two-step modelling approach of time to event and cognitive decline to inform Alzheimer’s disease prevention trials Thursday 15:10-16:40 |
| IV-10 Leticia Arrington A Model Based Meta-Analysis (MBMA) to support development of medicines for treatment of DPN, PHN and Fibromyalgia. Thursday 15:10-16:40 |
| IV-11 Hyeong-Seok Lim Pharmacokinetic and Pharmacodynamic Evaluation of Intravenous Levetiracetam in Children with Epilepsy Thursday 15:10-16:40 |
| IV-12 Sihang Liu Population PK/PD analysis of ropinirole as a potential treatment for hyperprolactinemia Thursday 15:10-16:40 |
| IV-13 Rasmus Jansson Löfmark Pharmacokinetic population modelling of a GLP1 beta cell targeting oligonucleotide Thursday 15:10-16:40 |
| IV-14 Philip Lowe Ligelizumab Paediatric Investigation Plan: exposure-response analysis in adult chronic spontaneous urticaria with simulation-based design of adolescent dose-finding Thursday 15:10-16:40 |
| IV-15 Qiang Lu Population pharmacokinetic analysis of dupilumab in adult and adolescent patients with asthma Thursday 15:10-16:40 |
| IV-16 Rubin Lubomirov Population pharmacokinetic-based targeted exome sequencing (PopPK-TES) approach to assess the impact of genetic variants on pharmacokinetics of lurbinectedin in patients with advanced cancer Thursday 15:10-16:40 |
| IV-17 Sreenath M Krishnan Accuracy in the estimation of the hazard in simultaneous and sequential estimation approaches of tumor size and overall survival (OS) modeling Thursday 15:10-16:40 |
| IV-18 Lei Ma Efpeglenatide dose selection for a phase 3 study in type 2 diabetes mellitus (T2DM) patients: pharmacokinetics and pharmacodynamics (PK/PD) modeling, network meta-analysis and clinical trial simulation Thursday 15:10-16:40 |
| IV-19 Matthias Machacek A Systems Pharmacology model of peripheral serotonin production proposing two different synthesis compartments with markedly different release rates into blood Thursday 15:10-16:40 |
| IV-20 Paolo Magni Evaluation of software tools for Bayesian estimation on population models: an update based on current software versions Thursday 15:10-16:40 |
| IV-21 Corinna Maier Improving model-based predictions of neutropenia using sequential data assimilation Thursday 15:10-16:40 |
| IV-22 Victor Mangas-Sanjuan Defining level A IVIVC dissolution specifications based on individual in vitro dissolution profiles Thursday 15:10-16:40 |
| IV-23 Jialin Mao PBPK modelling of drug-drug interactions driven by moderate CYP3A inducers Thursday 15:10-16:40 |
| IV-24 Anita Mathias Joint population pharmacokinetic modelling of sofosbuvir and its metabolites (GS-566500, GS-331007) in Hepatitis C Virus (HCV)-infected adolescents receiving sofosbuvir or ledipasvir/sofosbuvir Thursday 15:10-16:40 |
| IV-25 Tomomi Matsuura Clinical validation of a quantitative systems pharmacology (QSP) model for nerve-growth-factor (NGF) therapies Thursday 15:10-16:40 |
| IV-26 Hannah Mayer A novel approach to estimate ontogenies for PBPK applications – From literature data to simulations Thursday 15:10-16:40 |
| IV-27 Christophe Meille PKPD modeling of preclinical anti-tumor activity translates to first-in-human phase I study of MDM2 inhibitor HDM201 Thursday 15:10-16:40 |
| IV-28 Nicola Melillo Variance based Global Sensitivity Analysis of a Physiological Absorption model for compounds in different BCS classes Thursday 15:10-16:40 |
| IV-29 Johanna Melin Dapagliflozin pharmacokinetics is similar in adults with type 1 and type 2 diabetes mellitus Thursday 15:10-16:40 |
| IV-30 Matilde Merino-Sanjuán Evaluation of the impact of undernourishment on the intestinal absorption of gefitinib in rats. Thursday 15:10-16:40 |
| IV-31 Jonathan Mochel Modeling Primary Tumor Growth in a Xenograft Mouse Model of Non-Small Cell Lung Cancer Treated With Pemetrexed-Cisplatin and Bevacizumab Thursday 15:10-16:40 |
| IV-32 Claudio Monteiro Sousa An in silico HBV model predicts viral response to the oral non-steroidal carboxylic acid FXR agonist EYP001a. Thursday 15:10-16:40 |
| IV-33 Denise Morris Population Pharmacokinetic Modeling of Fremanezumab in Support of Phase 3 Development for Patients with Migraine Thursday 15:10-16:40 |
| IV-34 Ricardo Nalda-Molina Population Pharmacokinetics of Hyperthermic Intraoperative Peritoneal Oxaliplatin in Wistar Rats Thursday 15:10-16:40 |
| IV-35 Antonina Nikitich Immune Response Template for Quantitative Systems Pharmacology Modeling: Description of Co-inhibitory and Co-stimulatory Receptors Interaction Thursday 15:10-16:40 |
| IV-36 Asbjørn Nøhr-Nielsen A review of fixed-dose combination approvals in the EU based on European public assessment reports (EPARs) Thursday 15:10-16:40 |
| IV-37 Patrick Nolain PopkinR: a suite of Shiny applications focused on the pharmacometrics workflow Thursday 15:10-16:40 |
| IV-38 Rikard Nordgren Faster methods for case deletion diagnostics: dOFV and linearized dOFV Thursday 15:10-16:40 |
| IV-39 Ana Novakovic Simulation based assessment of flat dose regimen of an anti-PDL1 antibody: Case study of avelumab Thursday 15:10-16:40 |
| IV-40 Eric Novik Stan: an open source probabilistic programming language for high-performance statistical computing Thursday 15:10-16:40 |
| IV-41 Katharina Och A pharmacokinetic/pharmacodynamic model of cyclosporine A and its nephrotoxicity in patients after hematopoietic stem cell transplantation Thursday 15:10-16:40 |
| IV-42 Chika Ogami Population pharmacokinetics of unbound daptomycin in hospital patients with Gram-positive infections Thursday 15:10-16:40 |
| IV-43 Boram Ohk Population pharmacokinetics of sumatriptan in healthy korean subjects : sex differences Thursday 15:10-16:40 |
| IV-44 Andrés Olivares-Morales Switching from immediate release to modified release can have an impact on intestinal drug-drug interactions: A PBPK simulation study using oxybutynin as a case example Thursday 15:10-16:40 |
| IV-45 Erik Olofsen The definition and interpretation of utility functions Thursday 15:10-16:40 |
| IV-46 Sean Oosterholt Implications of a model-based dosing algorithm for tacrolimus in paediatric kidney transplantation Thursday 15:10-16:40 |
| IV-47 Taniya Paiboonvong Population Pharmacokinetics of Sitafloxacin in Thai Critically Ill Patients with Pneumonia Thursday 15:10-16:40 |
| IV-48 Kwan Cheol Pak Physiologically based pharmacokinetic modeling of Herceptin and human pharmacokinetic prediction Thursday 15:10-16:40 |
| IV-49 Semra Palic Exploring dose-dependent pharmacokinetics of miltefosine in pediatric visceral leishmaniasis patients from East Africa Thursday 15:10-16:40 |
| IV-50 - - Efficacy and toxicity of intravenous salbutamol in children with acute severe asthma: a prospective clinical PKPD study Thursday 15:10-16:40 |
| IV-51 Alice Panchaud Prediction of escitalopram exposure in infants through breastfeeding by modeling and simulation Thursday 15:10-16:40 |
| IV-52 Navarat Panjasawatwong Population pharmacokinetics of rifampicin in Vietnamese Children with Tuberculous Meningitis Thursday 15:10-16:40 |
| IV-53 Christophe Passot Therapeutic drug monitoring of eculizumab in atypical hemolytic uremic syndrome Thursday 15:10-16:40 |
| IV-54 Dimple Patel Using real world data to assess SGLT2 Inhibitor cardiovascular benefit and impacts of patient population characteristics Thursday 15:10-16:40 |
| IV-55 Henning Schmidt Reproducible submission-ready Word reports based on open source tools Thursday 15:10-16:40 |
| IV-56 Violeta Balbas-Martinez Physiologically-Based Pharmacokinetic model for Ciprofloxacin in healthy children and approximation to children with complicated Urinary Tract Infection Thursday 15:10-16:40 |
| IV-57 Cesar Pichardo QSP Modelling of Neurodegenerative Chronic Diseases and Brain Biomarkers: Adding the Effect of Ageing on Brain Volume Thursday 15:10-16:40 |
| IV-58 Philippe Pierrillas PKPD modelling of EYP001a (a novel FXR agonist) in healthy volunteers and Hepatitis B patients Thursday 15:10-16:40 |
| IV-59 Etienne Pigeolet Modeling of amyloid accumulation in subjects at risk of Alzheimer’s disease under BACE inhibition treatment. Thursday 15:10-16:40 |
| IV-60 Nikhil Pillai Estimating parameters of chaotic systems: chaos synchronization combined with Nelder-Mead search Thursday 15:10-16:40 |
| IV-61 Eduard Schmulenson A physiologically-based pharmacokinetic modeling approach to assess the impact of chronic kidney disease Thursday 15:10-16:40 |
| IV-62 Teun Post An HCV nucleoside inhibitor MK-3682 minimal PBPK-PD model for application in hypothesis generation regarding metabolic pathways and perturbations under various conditions Thursday 15:10-16:40 |
| IV-63 Manuel Prado-Velasco New approach based on physiological modelling to compute the bioavailability using the PhysPK biosimulation system Thursday 15:10-16:40 |
| IV-64 Jens Przybilla Epigenetic modelling of DNA demethylation therapy in Acute Myeloid Leukemia Thursday 15:10-16:40 |
| IV-65 Alicja Puszkiel Quantitative evaluation of the impact of CYP2D6 genetic polymorphisms on pharmacokinetics of tamoxifen and its metabolites in breast cancer patients Thursday 15:10-16:40 |
| IV-66 Luis Quintairos Domenech Pharmacodynamic modelling of biomarkers in kidney transplantation: a transformed binary data population approach Thursday 15:10-16:40 |
| IV-67 Hanne Refsgaard Steps Towards a Robust Generic Method for Deconvolution Directly on Pharmacokinetic Profiles Thursday 15:10-16:40 |
| IV-68 Theo Reijmers Population PK Modelling of Treosulfan in Paediatric Allogeneic Transplant Patients Thursday 15:10-16:40 |
| IV-69 François Riglet Multiple response modelling of mycophenolic acid pharmacokinetics in adult patients with transplanted kidneys by population approach Thursday 15:10-16:40 |
| IV-70 Christer Rimmler Evaluating New Dosing Strategies for the Use of Cefuroxime in Perioperative Antibiotic Prophylaxis using PBPK Thursday 15:10-16:40 |
| IV-71 Christelle Rodrigues A population pharmacokinetic model taking into account protein binding for the sustained-release granule formulation of valproic acid in children with epilepsy Thursday 15:10-16:40 |
| IV-72 Leire Ruiz Cerdá External validation of Systems Pharmacology Models of the Coagulation Network with published data Thursday 15:10-16:40 |
| IV-73 Yevgen Ryeznik Treatment allocation adaptive randomization methods in clinical trials with few individuals may influence model parameter estimation Thursday 15:10-16:40 |
| IV-74 Oliver Sander Detecting and Analyzing 5x Sit-to-Stand Tests from Accelerometer Data Thursday 15:10-16:40 |
| IV-75 Stein Schalkwijk Exploring Standard and Alternative Darunavir/Ritonavir Dosing Regimens for HIV-positive pregnant women using semi-mechanistic pharmacokinetic modeling Thursday 15:10-16:40 |
| IV-76 Stephan Schaller Towards Predictions of Clinical Trial Outcomes: Combining PBPK and QSP within a Translational Diabetes Disease Platform Thursday 15:10-16:40 |
